Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan.

Mushtaq, Saima; Akhter, Tayyab Saeed; Khan, Amjad; Sohail, Aamir; Khan, Arshad; Manzoor, Sobia

Mushtaq, Saima; Akhter, Tayyab Saeed; Khan, Amjad; Sohail, Aamir; Khan, Arshad; Manzoor, Sobia.

Affiliation

Mushtaq S; Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Akhter TS; Centre for Liver and Digestive Diseases, Holy Family Hospital, Rawalpindi Medical College and Allied Hospitals, Rawalpindi, Pakistan.
Khan A; Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
Sohail A; Department of Medicine, Karachi Institute of Medical Sciences, Combined Military Hospital, Karachi, Pakistan.
Khan A; Department of Neurosurgery, Medical Teaching Institution, Lady Reading Hospital, Peshawar, Pakistan.
Manzoor S; Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.

Front Pharmacol ; 11: 550205, 2020.

Article de En | MEDLINE | ID: mdl-32982753

Mots clés

daclatasvir; hepatitis C; sofosbuvir; sustained virological response; velpatasvir

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Front Pharmacol Année: 2020 Type de document: Article Pays d'affiliation: Pakistan

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google